Reach Markets Presentation on Wednesday, 4th November12pm (AEDT)Online 15 min:
Prescient Therapeutics (ASXTX) PTX is a biotechnology company focused on improving outcomes for cancer patients by developing personal medicines, including the spectacularly successful CAR-T and targeted therapy approaches. It is working in collaboration with the world-leading Peter MacCallum Cancer Centre to advance promising new personalised cancer therapies. The company recently completed a $6.5m Share Purchase Plan and a $7m follow-on placement, both of which were heavily oversubscribed. Part of the appeal stems from its global, exclusive license from the University of Pennsylvania for the next generation CAR-T platform ‘OmniCAR’.
PTX Price at posting:
5.8¢ Sentiment: Hold Disclosure: Held
TX) PTX is a biotechnology company focused on improving outcomes for cancer patients by developing personal medicines, including the spectacularly successful CAR-T and targeted therapy approaches. It is working in collaboration with the world-leading Peter MacCallum Cancer Centre to advance promising new personalised cancer therapies. The company recently completed a $6.5m Share Purchase Plan and a $7m follow-on placement, both of which were heavily oversubscribed. Part of the appeal stems from its global, exclusive license from the University of Pennsylvania for the next generation CAR-T platform ‘OmniCAR’.
